Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance

Cui, Lehui; Huang, L.; Pan, F.-F.; Wang, Y.; Huang, Q.; Guan, Yijia; Lo, C-Y.Z.; Guo, Y.-H.; Chan, A.S.; Xie, F.; Guo, Q.-H.

doi:10.14283/jpad.2023.49

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these databases, many breakthroughs have been made in AD-related gene loci, biomarker detection, PET molecular imaging, etc., which provide important support for screening target participants and therapeutic targets in AD clinical trials. Besides, GHABS also referred to several well-organized cohorts in China, such as the Beijing Aging Brain Rejuvenation Initiative [ 55 ], China Aging and Neurodegenerative Initiative [ 56 ], Chinese Alzheimer’s Biomarker and LifestylE [ 57 ], the Chongqing Ageing & Dementia Study (CADS) [ 58 ], Chinese Preclinical Alzheimer’s Disease Study (C-PAS) [ 59 ], the China Cognition and Ageing Study [ 60 ], the Taizhou Imaging Study [ 61 ], and Sino Longitudinal Study on Cognitive Decline [ 62 ]. Dr. Ying Han, the president of the “Pre-Alzheimer’s Disease Alliance of China,” is one of the principal investigators in GHABS.…”

Section: Discussionmentioning

confidence: 99%

Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)

Liu,

Shi,

Cai

et al. 2024

Alz Res Therapy

View full text Add to dashboard Cite

Introduction The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86 million population and faces a significant challenge of Alzheimer’s disease (AD). However, the characteristics and prevalence of AD in this area are still unclear due to the rarely available community-based neuroimaging AD cohort. Methods Following the standard protocols of the Alzheimer’s Disease Neuroimaging Initiative, the Greater-Bay-Area Healthy Aging Brain Study (GHABS) was initiated in 2021. GHABS participants completed clinical assessments, plasma biomarkers, genotyping, magnetic resonance imaging (MRI), β-amyloid (Aβ) positron emission tomography (PET) imaging, and tau PET imaging. The GHABS cohort focuses on pathophysiology characterization and early AD detection in the Guangdong-Hong Kong-Macao Greater Bay Area. In this study, we analyzed plasma Aβ42/Aβ40 (A), p-Tau181 (T), neurofilament light, and GFAP by Simoa in 470 Chinese older adults, and 301, 195, and 70 had MRI, Aβ PET, and tau PET, respectively. Plasma biomarkers, Aβ PET, tau PET, hippocampal volume, and temporal-metaROI cortical thickness were compared between normal control (NC), subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia groups, controlling for age, sex, and APOE-ε4. The prevalence of plasma A/T profiles and Aβ PET positivity were also determined in different diagnostic groups. Results The aims, study design, data collection, and potential applications of GHABS are summarized. SCD individuals had significantly higher plasma p-Tau181 and plasma GFAP than the NC individuals. MCI and dementia patients showed more abnormal changes in all the plasma and neuroimaging biomarkers than NC and SCD individuals. The frequencies of plasma A+/T+ (NC; 5.9%, SCD: 8.2%, MCI: 25.3%, dementia: 64.9%) and Aβ PET positivity (NC: 25.6%, SCD: 22.5%, MCI: 47.7%, dementia: 89.3%) were reported. Discussion The GHABS cohort may provide helpful guidance toward designing standard AD community cohorts in South China. This study, for the first time, reported the pathophysiology characterization of plasma biomarkers, Aβ PET, tau PET, hippocampal atrophy, and AD-signature cortical thinning, as well as the prevalence of Aβ PET positivity in the Guangdong-Hong Kong-Macao Greater Bay Area of China. These findings provide novel insights into understanding the characteristics of abnormal AD pathological changes in South China’s older population.

show abstract

Section: Discussionmentioning

confidence: 99%

Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)

Liu,

Shi,

Cai

et al. 2024

Alz Res Therapy

View full text Add to dashboard Cite

show abstract

“…Inclusion and exclusion criteria, clinical and neuroimaging protocols, and other information about C-PAS are described here. 51 The ethics committee of Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine reviewed and approved this study (2019-032), following the principles of the Declaration of Helsinki. Written informed consent was obtained from participants or their caregivers.…”

Section: Methodsmentioning

confidence: 99%

Increased intestinal bile acid absorption contributes to age-related cognitive impairment

Ren,

Zhao,

Zhao

et al. 2024

Cell Reports Medicine

View full text Add to dashboard Cite

fNIRS as a biomarker for individuals with subjective memory complaints and MCI

Lee,

Guo,

Chan

2024

Alzheimer's & Dementia

View full text Add to dashboard Cite

INTRODUCTIONIdentifying individuals at risk of developing dementia is crucial for early intervention. Mild cognitive impairment (MCI) and subjective memory complaints (SMCs) are considered its preceding stages. This study aimed to assess the utility of functional near‐infrared spectroscopy (fNIRS) in identifying individuals with MCI and SMC.METHODSOne hundred fifty‐one participants were categorized into normal cognition (NC); amnestic MCI (aMCI); non‐amnestic MCI (naMCI); and mild, moderate, and severe SMC groups. Task‐related prefrontal hemodynamics were measured using fNIRS during a visual memory span task.RESULTSResults showed significantly lower oxyhemoglobin (HbO) levels in aMCI, but not in naMCI, compared to the NC. In addition, severe SMC had lower HbO levels than the NC, mild, and moderate SMC. Receiver operating characteristic analysis demonstrated 69.23% and 69.70% accuracy in differentiating aMCI and severe SMC from NC, respectively.DISCUSSIONFNIRS may serve as a potential non‐invasive biomarker for early detection of dementia.Highlights Only amnestic mild cognitive impairment (aMCI), but not non‐amnestic MCI, showed lower oxyhemoglobin (HbO) than normal individuals. Reduced HbO was observed in those with severe subjective memory complaints (SMCs) compared to normal cognition (NC), mild, and moderate SMCs. Functional near‐infrared spectroscopy measures were associated with performance in memory assessments. Prefrontal hemodynamics could distinguish aMCI and severe SMC from NC.

show abstract

Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance

Cited by 8 publications

References 0 publications

Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)

Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)

Increased intestinal bile acid absorption contributes to age-related cognitive impairment

fNIRS as a biomarker for individuals with subjective memory complaints and MCI

Contact Info

Product

Resources

About